HK1252003A1 - 阿坎酸散剂 - Google Patents

阿坎酸散剂 Download PDF

Info

Publication number
HK1252003A1
HK1252003A1 HK18111332.4A HK18111332A HK1252003A1 HK 1252003 A1 HK1252003 A1 HK 1252003A1 HK 18111332 A HK18111332 A HK 18111332A HK 1252003 A1 HK1252003 A1 HK 1252003A1
Authority
HK
Hong Kong
Prior art keywords
acamprosate
sprinkle formulations
pellets
sprinkle
formulations
Prior art date
Application number
HK18111332.4A
Other languages
English (en)
Chinese (zh)
Inventor
Steven L. JOHNS
Kenneth G. PAYIE
Badrinath R. DONIPARTHI
Shivaraj B. MUNIANJANAPPA
Original Assignee
Confluence Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Confluence Pharmaceuticals, Llc filed Critical Confluence Pharmaceuticals, Llc
Publication of HK1252003A1 publication Critical patent/HK1252003A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
HK18111332.4A 2015-05-04 2016-05-04 阿坎酸散剂 HK1252003A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562156842P 2015-05-04 2015-05-04
US62/156,842 2015-05-04
US201562260161P 2015-11-25 2015-11-25
US62/260,161 2015-11-25

Publications (1)

Publication Number Publication Date
HK1252003A1 true HK1252003A1 (zh) 2019-05-10

Family

ID=57217823

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111332.4A HK1252003A1 (zh) 2015-05-04 2016-05-04 阿坎酸散剂

Country Status (10)

Country Link
US (1) US10709668B2 (https=)
EP (1) EP3291800A4 (https=)
JP (2) JP7026347B2 (https=)
KR (1) KR102790656B1 (https=)
AU (1) AU2016258624B2 (https=)
HK (1) HK1252003A1 (https=)
IL (1) IL255343B2 (https=)
SG (1) SG11201708393UA (https=)
WO (1) WO2016179252A1 (https=)
ZA (1) ZA201708037B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357469B2 (en) 2015-02-18 2019-07-23 Aston University Diagnostic assay and treatment for preeclampsia
SG11201708393UA (en) 2015-05-04 2017-11-29 Confluence Pharmaceuticals Llc Sprinkle formulations of acamprosate
HK1255584A1 (zh) * 2015-08-04 2019-08-23 Confluence Pharmaceuticals, Llc 使用阿坎酸及d-环丝胺酸的联合疗法
IL270654B2 (en) * 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof
ES2938609T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión
EP4213817A1 (en) * 2020-09-21 2023-07-26 Sun Pharmaceutical Industries Limited Multi-particulate pharmaceutical composition of quetiapine
EP4406479A4 (en) 2021-09-24 2025-05-07 Sumitomo Bakelite Co.Ltd. Brain wave detection electrode, brain wave measurement device, and brain wave measurement method

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
DE1073432T1 (de) 1998-04-14 2002-02-07 The General Hospital Corp., Boston Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
US20050042277A1 (en) * 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
JP2010532331A (ja) 2007-07-05 2010-10-07 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 抗痙攣医薬組成物
CA2781830C (en) 2009-02-12 2018-03-27 Indiana University Research & Technology Corporation Materials and methods for treating developmental disorders including comorbid and idiopathic autism
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
MX346203B (es) * 2010-09-28 2017-03-09 Depomed Inc Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior.
TR201809351T4 (tr) 2011-03-01 2018-07-23 Pharnext Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi.
DK3272342T3 (da) * 2011-03-23 2021-06-07 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse
JP5893135B2 (ja) 2011-06-28 2016-03-23 ビボゾーン インコーポレイテッド 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2014197744A1 (en) * 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2015217796B2 (en) 2014-02-11 2020-04-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
SG11201708393UA (en) 2015-05-04 2017-11-29 Confluence Pharmaceuticals Llc Sprinkle formulations of acamprosate

Also Published As

Publication number Publication date
US10709668B2 (en) 2020-07-14
EP3291800A1 (en) 2018-03-14
US20190046458A1 (en) 2019-02-14
KR102790656B1 (ko) 2025-04-02
JP7026347B2 (ja) 2022-02-28
JP2018515506A (ja) 2018-06-14
AU2016258624B2 (en) 2021-07-29
EP3291800A4 (en) 2018-09-26
SG11201708393UA (en) 2017-11-29
IL255343B2 (en) 2024-10-01
ZA201708037B (en) 2020-03-25
IL255343A0 (en) 2017-12-31
KR20170142180A (ko) 2017-12-27
WO2016179252A1 (en) 2016-11-10
JP2021155434A (ja) 2021-10-07
IL255343B1 (en) 2024-06-01
AU2016258624A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
HK1252003A1 (zh) 阿坎酸散剂
IL277417A (en) Spray epinephrine preparations
WO2018025089A3 (en) Intranasal pharmaceutical powder compositions
WO2016025803A8 (en) Systems and methods for synthesizing chemical products, including active pharmaceutical ingredients
WO2016001937A3 (en) Modified release pharmaceutical preparations
WO2017037594A3 (zh) 用于减少局部脂肪的医药组成物及其用途
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
HK1203815A1 (en) Pharmaceutical compositions and methods for their preparation
HK1259441A1 (zh) 包含btk抑制剂的制剂/组合物
IL290894A (en) pharmaceutical preparation
IL266205B (en) Microspheres that include an active pharmaceutical component and a fatty shield
WO2020099937A3 (en) Dihydromyricetin spray-dried dispersion formulations and methods for forming them
EP3806827A4 (en) EPINEPHRINE SPRAY FORMULATIONS
ZA201904403B (en) A stable, self-dispersible, low foaming solid pesticide formulation
PH12017502322A1 (en) Therapeutic agent for fibrosis
GB2552733B (en) Aerosol compositions having improved active ingredient application
ZA201806766B (en) Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
EP3573747A4 (en) PREPARATION OF MICROPARTICLES OF AN ACTIVE SUBSTANCE
IL262059A (en) A layer coated tablet with high chemical stability of the active ingredient
IL289901A (en) A stable preparation that includes herbicides
EP3654950A4 (en) MICROPARTICLE FORMULATIONS FOR THE DELIVERY OF ACTIVE INGREDIENTS
EP3654844A4 (en) DEVICES, SYSTEMS AND METHODS FOR DISPENSING SOLID FORMULATIONS
WO2019101937A3 (en) Inhibitors of the shikimate pathway and use of 7-deoxy-sedoheptulose as antimicrobial and herbicidal agent
WO2015195711A3 (en) Method and devices for manufacturing and delivering of aerosolized formulations
GB201906473D0 (en) Pharmaceutical formulation